News & Analysis as of

Alexion › Pharmaceutical Industry › Life Sciences

Rothwell, Figg, Ernst & Manbeck, P.C.

As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion

Rothwell, Figg, Ernst & Manbeck, P.C. on

AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which...more

Kramer Levin Naftalis & Frankel LLP

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

Kramer Levin Naftalis & Frankel LLP on

Amgen Inc. and Alexion Pharmaceuticals Inc. settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide